OBJECTIVE: This study aimed to compare the effects of three different hemostatic agents on surgical and early renal functional outcomes after laparoscopic partial nephrectomy (LPN). MATERIALS AND METHODS: A total of 126 cases of LPN performed between November 2008 and September 2016 were enrolled in this study. Spongostan™ Absorbable Hemostatic Gelatin Sponge (Ethicon, Somerville, NJ, USA) or Surgicel® Original Absorbable Hemostat (Ethicon, Somerville, NJ, USA), or a total of 5 mL of Floseal® Hemostatic Matrix (Baxter Healthcare, Deerfield, IL) was used for additional hemostasis. According to the hemostatic agent used, patients were divided into three groups; and patient characteristics, body mass index (BMI), American Society of Anesthesiologists (ASA) score, tumor characteristics, perioperative parameters, serum creatinine levels, and complications were compared among these three groups. RESULTS: Age, BMI, ASA score, tumor characteristics, operative time, warm ischemia time, complication rates, and length of hospital stay were similar among the groups, whereas estimated blood loss was significantly lower in the Floseal Group (p=0.01). Postoperative serum creatinine levels and differences between preoperative and postoperative serum creatinine levels were also similar among the groups. CONCLUSION: The type of hemostatic agent used in LPN may affect the estimated blood loss. However, it has no substantial effect on other surgical parameters and early renal functional outcomes.
OBJECTIVE: This study aimed to compare the effects of three different hemostatic agents on surgical and early renal functional outcomes after laparoscopic partial nephrectomy (LPN). MATERIALS AND METHODS: A total of 126 cases of LPN performed between November 2008 and September 2016 were enrolled in this study. Spongostan™ Absorbable Hemostatic Gelatin Sponge (Ethicon, Somerville, NJ, USA) or Surgicel® Original Absorbable Hemostat (Ethicon, Somerville, NJ, USA), or a total of 5 mL of Floseal® Hemostatic Matrix (Baxter Healthcare, Deerfield, IL) was used for additional hemostasis. According to the hemostatic agent used, patients were divided into three groups; and patient characteristics, body mass index (BMI), American Society of Anesthesiologists (ASA) score, tumor characteristics, perioperative parameters, serum creatinine levels, and complications were compared among these three groups. RESULTS: Age, BMI, ASA score, tumor characteristics, operative time, warm ischemia time, complication rates, and length of hospital stay were similar among the groups, whereas estimated blood loss was significantly lower in the Floseal Group (p=0.01). Postoperative serum creatinine levels and differences between preoperative and postoperative serum creatinine levels were also similar among the groups. CONCLUSION: The type of hemostatic agent used in LPN may affect the estimated blood loss. However, it has no substantial effect on other surgical parameters and early renal functional outcomes.
Authors: Frank Richter; Dietmar Schnorr; Serdar Deger; Ingolf Trk; Jan Roigas; Andreas Wille; Stephan A Loening Journal: Urology Date: 2003-01 Impact factor: 2.649
Authors: David S Finley; David I Lee; Louis Eichel; Carlos A Uribe; Elspeth M McDougall; Ralph V Clayman Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: Alberto Breda; Sevan V Stepanian; John S Lam; Joseph C Liao; Inderbir S Gill; Jose R Colombo; Giorgio Guazzoni; Michael D Stifelman; Kent T Perry; Antonio Celia; Guglielmo Breda; Paolo Fornara; Stephen V Jackman; Antonio Rosales; Juan Palou; Michael Grasso; Vincenzo Pansadoro; Vincenzo Disanto; Francesco Porpiglia; Claudio Milani; Claude C Abbou; Richard Gaston; Gunter Janetschek; Naeem A Soomro; Jean J De la Rosette; Pilar M Laguna; Peter G Schulam Journal: Eur Urol Date: 2007-02-22 Impact factor: 20.096
Authors: Stefan Siemer; Sven Lahme; Stefan Altziebler; Stefan Machtens; Walter Strohmaier; Hans-W Wechsel; Peter Goebell; Nicolaus Schmeller; Ralph Oberneder; Jens-Uwe Stolzenburg; Hermann Becker; Werner Lüftenegger; Vilhelm Tetens; Hein Van Poppel Journal: Eur Urol Date: 2007-04-18 Impact factor: 20.096